Search

Your search keyword '"Ton, N"' showing total 1,628 results
Start Over Author "Ton, N"
1,628 results on '"Ton, N"'

51. The “cancer immunogram”

Author

Blank, Christian U, Haanen, John B, Ribas, Antoni, and Schumacher, Ton N

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Lung Cancer, Lung, Immunization, Vaccine Related, Cancer, Good Health and Well Being, Animals, Biomarkers, Tumor, Humans, Immunotherapy, Lymphocytes, Tumor-Infiltrating, Macrophages, Mice, Microbiota, Neoplasms, Precision Medicine, T-Lymphocytes, Tumor Escape, General Science & Technology
Abstract

Visualizing the state of cancer–immune system interactions may spur personalized therapy

Published
2016

52. CANCER IMMUNOLOGY. The "cancer immunogram".

Author

Blank, Christian U, Haanen, John B, Ribas, Antoni, and Schumacher, Ton N

Subjects
T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Macrophages, Animals, Humans, Mice, Neoplasms, Immunotherapy, Tumor Escape, Microbiota, Biomarkers, Tumor, Precision Medicine, Lymphocytes, Tumor-Infiltrating, Biomarkers, Tumor, General Science & Technology
Published
2016

53. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Author

van Dijk, Nick, Gil-Jimenez, Alberto, Silina, Karina, Hendricksen, Kees, Smit, Laura A., de Feijter, Jeantine M., van Montfoort, Maurits L., van Rooijen, Charlotte, Peters, Dennis, Broeks, Annegien, van der Poel, Henk G., Bruining, Annemarie, Lubeck, Yoni, Sikorska, Karolina, Boellaard, Thierry N., Kvistborg, Pia, Vis, Daniel J., Hooijberg, Erik, Schumacher, Ton N., van den Broek, Maries, Wessels, Lodewyk F. A., Blank, Christian U., van Rhijn, Bas W., and van der Heijden, Michiel S.

Published
2020
Full Text
View/download PDF

54. Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features

Author

Gangaev, Anastasia, Ketelaars, Steven L. C., Isaeva, Olga I., Patiwael, Sanne, Dopler, Anna, Hoefakker, Kelly, De Biasi, Sara, Gibellini, Lara, Mussini, Cristina, Guaraldi, Giovanni, Girardis, Massimo, Ormeno, Cami M. P. Talavera, Hekking, Paul J. M., Lardy, Neubury M., Toebes, Mireille, Balderas, Robert, Schumacher, Ton N., Ovaa, Huib, Cossarizza, Andrea, and Kvistborg, Pia

Published
2021
Full Text
View/download PDF

55. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

Author

Vos, Joris L., Elbers, Joris B. W., Krijgsman, Oscar, Traets, Joleen J. H., Qiao, Xiaohang, van der Leun, Anne M., Lubeck, Yoni, Seignette, Iris M., Smit, Laura A., Willems, Stefan M., van den Brekel, Michiel W. M., Dirven, Richard, Baris Karakullukcu, M., Karssemakers, Luc, Klop, W. Martin C., Lohuis, Peter J. F. M., Schreuder, Willem H., Smeele, Ludi E., van der Velden, Lilly-Ann, Bing Tan, I., Onderwater, Suzanne, Jasperse, Bas, Vogel, Wouter V., Al-Mamgani, Abrahim, Keijser, Astrid, van der Noort, Vincent, Broeks, Annegien, Hooijberg, Erik, Peeper, Daniel S., Schumacher, Ton N., Blank, Christian U., de Boer, Jan Paul, Haanen, John B. A. G., and Zuur, Charlotte L.

Published
2021
Full Text
View/download PDF

56. Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection

Author

Francisco Caiado, Diogo Maia-Silva, Carolina Jardim, Nina Schmolka, Tânia Carvalho, Cláudia Reforço, Rita Faria, Branka Kolundzija, André E. Simões, Tuncay Baubec, Christopher R. Vakoc, Maria Gomes da Silva, Markus G. Manz, Ton N. Schumacher, Håkan Norell, and Bruno Silva-Santos

Subjects
Science
Abstract

The development of post-chemotherapy resistance is a significant issue in the management of AML. Here, Caiado et al. suggest that the issue might be circumvented via upfront combination with hypomethylating agents that shape the clonal dynamics and transcriptional landscape of relapsing AML

Published
2019
Full Text
View/download PDF

57. Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells

Author

Elisa Matas-Rico, Elselien Frijlink, Irene van der Haar Àvila, Apostolos Menegakis, Maaike van Zon, Andrew J. Morris, Jan Koster, Fernando Salgado-Polo, Sander de Kivit, Telma Lança, Antonio Mazzocca, Zoë Johnson, John Haanen, Ton N. Schumacher, Anastassis Perrakis, Inge Verbrugge, Joost H. van den Berg, Jannie Borst, and Wouter H. Moolenaar

Subjects
lysophosphatidic acid, autotaxin, chemorepulsion, T cells, G protein-coupled receptors, tumor microenvironment, Biology (General), QH301-705.5
Abstract

Summary: Autotaxin (ATX; ENPP2) produces lysophosphatidic acid (LPA) that regulates multiple biological functions via cognate G protein-coupled receptors LPAR1-6. ATX/LPA promotes tumor cell migration and metastasis via LPAR1 and T cell motility via LPAR2, yet its actions in the tumor immune microenvironment remain unclear. Here, we show that ATX secreted by melanoma cells is chemorepulsive for tumor-infiltrating lymphocytes (TILs) and circulating CD8+ T cells ex vivo, with ATX functioning as an LPA-producing chaperone. Mechanistically, T cell repulsion predominantly involves Gα12/13-coupled LPAR6. Upon anti-cancer vaccination of tumor-bearing mice, ATX does not affect the induction of systemic T cell responses but, importantly, suppresses tumor infiltration of cytotoxic CD8+ T cells and thereby impairs tumor regression. Moreover, single-cell data from melanoma tumors are consistent with intratumoral ATX acting as a T cell repellent. These findings highlight an unexpected role for the pro-metastatic ATX-LPAR axis in suppressing CD8+ T cell infiltration to impede anti-tumor immunity, suggesting new therapeutic opportunities.

Published
2021
Full Text
View/download PDF

59. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Author

Chalabi, Myriam, Fanchi, Lorenzo F., Dijkstra, Krijn K., Van den Berg, José G., Aalbers, Arend G., Sikorska, Karolina, Lopez-Yurda, Marta, Grootscholten, Cecile, Beets, Geerard L., Snaebjornsson, Petur, Maas, Monique, Mertz, Marjolijn, Veninga, Vivien, Bounova, Gergana, Broeks, Annegien, Beets-Tan, Regina G., de Wijkerslooth, Thomas R., van Lent, Anja U., Marsman, Hendrik A., Nuijten, Elvira, Kok, Niels F., Kuiper, Maria, Verbeek, Wieke H., Kok, Marleen, Van Leerdam, Monique E., Schumacher, Ton N., Voest, Emile E., and Haanen, John B.

Published
2020
Full Text
View/download PDF

62. A small proton charge radius from an electron–proton scattering experiment

Author

Xiong, W., Gasparian, A., Gao, H., Dutta, D., Khandaker, M., Liyanage, N., Pasyuk, E., Peng, C., Bai, X., Ye, L., Gnanvo, K., Gu, C., Levillain, M., Yan, X., Higinbotham, D. W., Meziane, M., Ye, Z., Adhikari, K., Aljawrneh, B., Bhatt, H., Bhetuwal, D., Brock, J., Burkert, V., Carlin, C., Deur, A., Di, D., Dunne, J., Ekanayaka, P., El-Fassi, L., Emmich, B., Gan, L., Glamazdin, O., Kabir, M. L., Karki, A., Keith, C., Kowalski, S., Lagerquist, V., Larin, I., Liu, T., Liyanage, A., Maxwell, J., Meekins, D., Nazeer, S. J., Nelyubin, V., Nguyen, H., Pedroni, R., Perdrisat, C., Pierce, J., Punjabi, V., Shabestari, M., Shahinyan, A., Silwal, R., Stepanyan, S., Subedi, A., Tarasov, V. V., Ton, N., Zhang, Y., and Zhao, Z. W.

Published
2019
Full Text
View/download PDF

63. Defining ‘T cell exhaustion’

Author

Blank, Christian U., Haining, W. Nicholas, Held, Werner, Hogan, Patrick G., Kallies, Axel, Lugli, Enrico, Lynn, Rachel C., Philip, Mary, Rao, Anjana, Restifo, Nicholas P., Schietinger, Andrea, Schumacher, Ton N., Schwartzberg, Pamela L., Sharpe, Arlene H., Speiser, Daniel E., Wherry, E. John, Youngblood, Benjamin A., and Zehn, Dietmar

Published
2019
Full Text
View/download PDF

64. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Author

Rozeman, Elisa A, Menzies, Alexander M, van Akkooi, Alexander C J, Adhikari, Chandra, Bierman, Carolien, van de Wiel, Bart A, Scolyer, Richard A, Krijgsman, Oscar, Sikorska, Karolina, Eriksson, Hanna, Broeks, Annegien, van Thienen, Johannes V, Guminski, Alexander D, Acosta, Alex Torres, ter Meulen, Sylvia, Koenen, Anne Miek, Bosch, Linda J W, Shannon, Kerwin, Pronk, Loes M, Gonzalez, Maria, Ch'ng, Sydney, Grijpink-Ongering, Lindsay G, Stretch, Jonathan, Heijmink, Stijn, van Tinteren, Harm, Haanen, John B A G, Nieweg, Omgo E, Klop, Willem M C, Zuur, Charlotte L, Saw, Robyn P M, van Houdt, Winan J, Peeper, Daniel S, Spillane, Andrew J, Hansson, Johan, Schumacher, Ton N, Long, Georgina V, and Blank, Christian U

Published
2019
Full Text
View/download PDF

66. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer

Author

Leonie Voorwerk, Olga I. Isaeva, Hugo M. Horlings, Sara Balduzzi, Maksim Chelushkin, Noor A. M. Bakker, Elisa Champanhet, Hannah Garner, Karolina Sikorska, Claudette E. Loo, Inge Kemper, Ingrid A. M. Mandjes, Michiel de Maaker, Jasper J. L. van Geel, Jorianne Boers, Maaike de Boer, Roberto Salgado, Marloes G. J. van Dongen, Gabe S. Sonke, Karin E. de Visser, Ton N. Schumacher, Christian U. Blank, Lodewyk F. A. Wessels, Agnes Jager, Vivianne C. G. Tjan-Heijnen, Carolien P. Schröder, Sabine C. Linn, Marleen Kok, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Epidemiology, and Medical Oncology

Subjects
EXPRESSION, Cancer Research, LOCALLY RECURRENT, Oncology, SDG 3 - Good Health and Well-being, CARCINOMA, FEATURES, MULTICENTER, SURVIVAL, CRITERIA, IMMUNOTHERAPY, CHEMOTHERAPY, SIGNATURES
Abstract

Invasive lobular breast cancer (ILC) is the second most common histological breast cancer subtype, but ILC-specific trials are lacking. Translational research revealed an immune-related ILC subset, and in mouse ILC models, synergy between immune checkpoint blockade and platinum was observed. In the phase II GELATO trial (NCT03147040), patients with metastatic ILC were treated with weekly carboplatin (area under the curve 1.5 mg ml–1 min–1) as immune induction for 12 weeks and atezolizumab (PD-L1 blockade; triweekly) from the third week until progression. Four of 23 evaluable patients had a partial response (17%), and 2 had stable disease, resulting in a clinical benefit rate of 26%. From these six patients, four had triple-negative ILC (TN-ILC). We observed higher CD8+ T cell infiltration, immune checkpoint expression and exhausted T cells after treatment. With this GELATO trial, we show that ILC-specific clinical trials are feasible and demonstrate promising antitumor activity of atezolizumab with carboplatin, particularly for TN-ILC, and provide insights for the design of highly needed ILC-specific trials.

Published
2023

67. Formation of Tissue-Resident CD8

Author

Feline E, Dijkgraaf, Lianne, Kok, and Ton N M, Schumacher

Subjects
Memory T Cells, Animals, Humans, Cell Differentiation, CD8-Positive T-Lymphocytes, Immunologic Memory
Abstract

Resident memory CD8

Published
2023

68. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis

Author

Wellenstein, Max D., Coffelt, Seth B., Duits, Danique E. M., van Miltenburg, Martine H., Slagter, Maarten, de Rink, Iris, Henneman, Linda, Kas, Sjors M., Prekovic, Stefan, Hau, Cheei-Sing, Vrijland, Kim, Drenth, Anne Paulien, de Korte-Grimmerink, Renske, Schut, Eva, van der Heijden, Ingrid, Zwart, Wilbert, Wessels, Lodewyk F. A., Schumacher, Ton N., Jonkers, Jos, and de Visser, Karin E.

Published
2019
Full Text
View/download PDF

70. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Author

Voorwerk, Leonie, Slagter, Maarten, Horlings, Hugo M., Sikorska, Karolina, van de Vijver, Koen K., de Maaker, Michiel, Nederlof, Iris, Kluin, Roelof J. C., Warren, Sarah, Ong, SuFey, Wiersma, Terry G., Russell, Nicola S., Lalezari, Ferry, Schouten, Philip C., Bakker, Noor A. M., Ketelaars, Steven L. C., Peters, Dennis, Lange, Charlotte A. H., van Werkhoven, Erik, van Tinteren, Harm, Mandjes, Ingrid A. M., Kemper, Inge, Onderwater, Suzanne, Chalabi, Myriam, Wilgenhof, Sofie, Haanen, John B. A. G., Salgado, Roberto, de Visser, Karin E., Sonke, Gabe S., Wessels, Lodewyk F. A., Linn, Sabine C., Schumacher, Ton N., Blank, Christian U., and Kok, Marleen

Published
2019
Full Text
View/download PDF

73. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Author

Blank, Christian U., Rozeman, Elisa A., Fanchi, Lorenzo F., Sikorska, Karolina, van de Wiel, Bart, Kvistborg, Pia, Krijgsman, Oscar, van den Braber, Marlous, Philips, Daisy, Broeks, Annegien, van Thienen, Johannes V., Mallo, Henk A., Adriaansz, Sandra, ter Meulen, Sylvia, Pronk, Loes M., Grijpink-Ongering, Lindsay G., Bruining, Annemarie, Gittelman, Rachel M., Warren, Sarah, van Tinteren, Harm, Peeper, Daniel S., Haanen, John B. A. G., van Akkooi, Alexander C. J., and Schumacher, Ton N.

Published
2018
Full Text
View/download PDF

74. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

Author

Natasja L. de Vries, Joris van de Haar, Vivien Veninga, Myriam Chalabi, Marieke E. Ijsselsteijn, Manon van der Ploeg, Jitske van den Bulk, Dina Ruano, Jose G. van den Berg, John B. Haanen, Laurien J. Zeverijn, Birgit S. Geurts, Gijs F. de Wit, Thomas W. Battaglia, Hans Gelderblom, Henk M. W. Verheul, Ton N. Schumacher, Lodewyk F. A. Wessels, Frits Koning, Noel F. C. C. de Miranda, Emile E. Voest, and Medical Oncology

Subjects
Multidisciplinary, SDG 3 - Good Health and Well-being
Abstract

DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB)1,2. Here, in contrast to other cancer types3–5, we observed that 20 out of 21 (95%) MMR-d cancers with genomic inactivation of β2-microglobulin (encoded by B2M) retained responsiveness to ICB, suggesting the involvement of immune effector cells other than CD8+ T cells in this context. We next identified a strong association between B2M inactivation and increased infiltration by γδ T cells in MMR-d cancers. These γδ T cells mainly comprised the Vδ1 and Vδ3 subsets, and expressed high levels of PD-1, other activation markers, including cytotoxic molecules, and a broad repertoire of killer-cell immunoglobulin-like receptors. In vitro, PD-1+ γδ T cells that were isolated from MMR-d colon cancers exhibited enhanced reactivity to human leukocyte antigen (HLA)-class-I-negative MMR-d colon cancer cell lines and B2M-knockout patient-derived tumour organoids compared with antigen-presentation-proficient cells. By comparing paired tumour samples from patients with MMR-d colon cancer that were obtained before and after dual PD-1 and CTLA-4 blockade, we found that immune checkpoint blockade substantially increased the frequency of γδ T cells in B2M-deficient cancers. Taken together, these data indicate that γδ T cells contribute to the response to immune checkpoint blockade in patients with HLA-class-I-negative MMR-d colon cancers, and underline the potential of γδ T cells in cancer immunotherapy.

Published
2023

76. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Author

Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Biochemistry, CCA - Cancer Treatment and Quality of Life, AII - Cancer immunology, Landsteiner Laboratory, General Internal Medicine, Health Technology & Services Research, Health Technology Assessment (HTA), Medical Oncology, Erasmus MC other, Surgery, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
Adoptive, Cell- and Tissue-Based Therapy, Outcomes, Dermatology, Metastatic melanoma, Guidelines, Immunotherapy, Adoptive, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Lymphocytes, Tumor-Infiltrating, SDG 3 - Good Health and Well-being, Adoption, Humans, Melanoma/drug therapy, Lymphocytes, Tumor-Infiltrating, Melanoma, Skin Cancer, Treatments in Oncology, Cancer, General Medicine, Complete responses, Hematology/Oncology, Ipilimumab, n/a OA procedure, Adoptive cell therapy, Nivolumab, Ipilimumab/adverse effects, Immunotherapy
Abstract

Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking to determine the role of TILs in treating advanced melanoma. METHODS: In this phase 3, multicenter, open-label trial, we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy (ipilimumab at 3 mg per kilogram of body weight). Infusion of at least 5×10(9) TILs was preceded by nonmyeloablative, lymphodepleting chemotherapy (cyclophosphamide plus fludarabine) and followed by high-dose interleukin-2. The primary end point was progression-free survival. RESULTS: A total of 168 patients (86% with disease refractory to anti-programmed death 1 treatment) were assigned to receive TILs (84 patients) or ipilimumab (84 patients). In the intention-to-treat population, median progression-free survival was 7.2 months (95% confidence interval [CI], 4.2 to 13.1) in the TIL group and 3.1 months (95% CI, 3.0 to 4.3) in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P

Published
2022

77. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

Author

Joost H van den Berg, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Marit M van Buuren, Henk Mallo, Matthias Karger, Joris A van der Hage, Loes M Pronk, Marnix H Geukes Foppen, Bastiaan Nuijen, and Ton N Schumacher

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Purpose Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.Experimental Ten patients were treated with TIL therapy. Infusion products and peripheral blood samples were phenotypically characterized and neoantigen reactivity was assessed. Here, we present long-term clinical outcome and translational data on neoantigen reactivity of the T cell products.Results Five out of 10 patients, who were all anti-PD-1 naïve at time of treatment, showed an objective clinical response, including two patients with a complete response that are both ongoing for more than 7 years. Immune monitoring demonstrated that neoantigen-specific T cells were detectable in TIL infusion products from three out of three patients analyzed. For six out of the nine neoantigen-specific T cell responses detected in these TIL products, T cell response magnitude increased significantly in the peripheral blood compartment after therapy, and neoantigen-specific T cells were detectable for up to 3 years after TIL infusion.Conclusion The clinical results from this study confirm the robustness of TIL therapy in metastatic melanoma and the potential role of neoantigen-specific T cell reactivity. In addition, the data from this study supported the rationale to initiate an ongoing multicenter phase III TIL trial.

Published
2020
Full Text
View/download PDF

78. Comprehensive analysis of cutaneous and uveal melanoma liver metastases

Author

Annegien Broeks, Sarah Warren, Pia Kvistborg, Richard A Scolyer, Esmee P Hoefsmit, Elisa A Rozeman, Trieu My Van, Petros Dimitriadis, Oscar Krijgsman, Jordan W Conway, Jacqueline E van der Wal, Steven L C Ketelaars, Kaspar Bresser, Ron M Kerkhoven, Jason W Reeves, Ellen W Kapiteijn, Daniel S Peeper, and Ton N M Schumacher

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background The profound disparity in response to immune checkpoint blockade (ICB) by cutaneous melanoma (CM) and uveal melanoma (UM) patients is not well understood. Therefore, we characterized metastases of CM and UM from the same metastatic site (liver), in order to dissect the potential underlying mechanism in differential response on ICB.Methods Tumor liver samples from CM (n=38) and UM (n=28) patients were analyzed at the genomic (whole exome sequencing), transcriptional (RNA sequencing) and protein (immunohistochemistry and GeoMx Digital Spatial Profiling) level.Results Comparison of CM and UM metastases from the same metastatic site revealed that, although originating from the same melanocyte lineage, CM and UM differed in somatic mutation profile, copy number profile, tumor mutational burden (TMB) and consequently predicted neoantigens. A higher melanin content and higher expression of the melanoma differentiation antigen MelanA was observed in liver metastases of UM patients. No difference in B2M and human leukocyte antigen-DR (HLA-DR) expression was observed. A higher expression of programmed cell death ligand 1 (PD-L1) was found in CM compared with UM liver metastases, although the majority of CM and UM liver metastases lacked PD-L1 expression. There was no difference in the extent of immune infiltration observed between CM and UM metastases, with the exception of a higher expression of CD163 (p

Published
2020
Full Text
View/download PDF

84. Effects of transglutaminase treatment on cooking quality, textural properties, and overall acceptability of high fibre pasta incorporated with pennywort residue.

Author

Le, N. P., Tran, T. T. T., Ton, N. M. N., and Le, V. V. M.

Subjects
PASTA products, PASTA, G proteins, FIBERS, TENSILE strength, SEMOLINA
Abstract

Pennywort juice is a herbal drink extracted from pennywort leaves and stems. Pennywort residue is a by-product of pennywort juice production. In the present work, this by-product was proved to be a good dietary fibre ingredient in the making of high fibre pasta. Nevertheless, the addition of 10% pennywort residue reduced cooking properties, textural profiles, and overall acceptability of the pasta samples. The effects of transglutaminase treatment of pasta dough on the product quality were then investigated. Increase in transglutaminase dosage from 0.00 to 0.75 U/g protein of the flour blend decreased the cooking loss of pasta by 19% while improving its tensile strength and elongation rate by 15 and 49%, respectively. Further increase in enzyme dosage from 0.75 to 1.00 U/g protein, on the other hand, decreased the tensile strength and elongation rate. When the enzyme treatment lasted for 30 min, the cooking loss was reduced by 10%, while the tensile strength and elongation rate of high fibre pasta were both enhanced by 10%. However, increase in treatment time from 30 to 40 min did not cause any significant differences in textural and cooking properties of the fibre-rich pasta. The appropriate transglutaminase dosage and biocatalytic time were 0.75 U/g protein and 30 min, respectively, under which the overall acceptability of the sample incorporated with 10% pennywort residue powder was similar to that of the semolina pasta. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

85. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

Author

Thommen, Daniela S., Koelzer, Viktor H., Herzig, Petra, Roller, Andreas, Trefny, Marcel, Dimeloe, Sarah, Kiialainen, Anna, Hanhart, Jonathan, Schill, Catherine, Hess, Christoph, Savic Prince, Spasenija, Wiese, Mark, Lardinois, Didier, Ho, Ping-Chih, Klein, Christian, Karanikas, Vaios, Mertz, Kirsten D., Schumacher, Ton N., and Zippelius, Alfred

Published
2018
Full Text
View/download PDF

86. Supplementary File S1 from Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells

Author

Prota, Gennaro, primary, Gileadi, Uzi, primary, Rei, Margarida, primary, Lechuga-Vieco, Ana Victoria, primary, Chen, Ji-Li, primary, Galiani, Silvia, primary, Bedard, Melissa, primary, Lau, Vivian Wing Chong, primary, Fanchi, Lorenzo F., primary, Artibani, Mara, primary, Hu, Zhiyuan, primary, Gordon, Siamon, primary, Rehwinkel, Jan, primary, Enríquez, Jose A., primary, Ahmed, Ahmed A., primary, Schumacher, Ton N., primary, and Cerundolo, Vincenzo, primary

Published
2023
Full Text
View/download PDF

87. Data from Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells

Author

Prota, Gennaro, primary, Gileadi, Uzi, primary, Rei, Margarida, primary, Lechuga-Vieco, Ana Victoria, primary, Chen, Ji-Li, primary, Galiani, Silvia, primary, Bedard, Melissa, primary, Lau, Vivian Wing Chong, primary, Fanchi, Lorenzo F., primary, Artibani, Mara, primary, Hu, Zhiyuan, primary, Gordon, Siamon, primary, Rehwinkel, Jan, primary, Enríquez, Jose A., primary, Ahmed, Ahmed A., primary, Schumacher, Ton N., primary, and Cerundolo, Vincenzo, primary

Published
2023
Full Text
View/download PDF

89. Data from Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells

Author

Di Lorenzo, Biagio, primary, Simões, André E., primary, Caiado, Francisco, primary, Tieppo, Paola, primary, Correia, Daniel V., primary, Carvalho, Tânia, primary, da Silva, Maria Gomes, primary, Déchanet-Merville, Julie, primary, Schumacher, Ton N., primary, Prinz, Immo, primary, Norell, Haakan, primary, Ravens, Sarina, primary, Vermijlen, David, primary, and Silva-Santos, Bruno, primary

Published
2023
Full Text
View/download PDF

91. Abstract 2281: Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment

Author

van der Leun, Anne M., primary, Traets, Joleen J., additional, Vos, Joris L., additional, Elbers, Joris B., additional, Patiwael, Sanne, additional, Qiao, Xiaohang, additional, Machuca-Ostos, Mercedes, additional, Thommen, Daniela S., additional, Haanen, John B., additional, Schumacher, Ton N., additional, and Zuur, Charlotte L., additional

Published
2023
Full Text
View/download PDF

95. Supplementary Figures and Tables from Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells

Author

Di Lorenzo, Biagio, primary, Simões, André E., primary, Caiado, Francisco, primary, Tieppo, Paola, primary, Correia, Daniel V., primary, Carvalho, Tânia, primary, da Silva, Maria Gomes, primary, Déchanet-Merville, Julie, primary, Schumacher, Ton N., primary, Prinz, Immo, primary, Norell, Haakan, primary, Ravens, Sarina, primary, Vermijlen, David, primary, and Silva-Santos, Bruno, primary

Published
2023
Full Text
View/download PDF

97. Supplementary Figures and Tables from Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells

Author

Prota, Gennaro, primary, Gileadi, Uzi, primary, Rei, Margarida, primary, Lechuga-Vieco, Ana Victoria, primary, Chen, Ji-Li, primary, Galiani, Silvia, primary, Bedard, Melissa, primary, Lau, Vivian Wing Chong, primary, Fanchi, Lorenzo F., primary, Artibani, Mara, primary, Hu, Zhiyuan, primary, Gordon, Siamon, primary, Rehwinkel, Jan, primary, Enríquez, Jose A., primary, Ahmed, Ahmed A., primary, Schumacher, Ton N., primary, and Cerundolo, Vincenzo, primary

Published
2023
Full Text
View/download PDF

98. Table S1 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy

Author

Pelly, Victoria S., primary, Moeini, Agrin, primary, Roelofsen, Lisanne M., primary, Bonavita, Eduardo, primary, Bell, Charlotte R., primary, Hutton, Colin, primary, Blanco-Gomez, Adrian, primary, Banyard, Antonia, primary, Bromley, Christian P., primary, Flanagan, Eimear, primary, Chiang, Shih-Chieh, primary, Jørgensen, Claus, primary, Schumacher, Ton N., primary, Thommen, Daniela S., primary, and Zelenay, Santiago, primary

Published
2023
Full Text
View/download PDF

99. Data from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy

Author

Pelly, Victoria S., primary, Moeini, Agrin, primary, Roelofsen, Lisanne M., primary, Bonavita, Eduardo, primary, Bell, Charlotte R., primary, Hutton, Colin, primary, Blanco-Gomez, Adrian, primary, Banyard, Antonia, primary, Bromley, Christian P., primary, Flanagan, Eimear, primary, Chiang, Shih-Chieh, primary, Jørgensen, Claus, primary, Schumacher, Ton N., primary, Thommen, Daniela S., primary, and Zelenay, Santiago, primary

Published
2023
Full Text
View/download PDF

100. Supplementary Data from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy

Author

Pelly, Victoria S., primary, Moeini, Agrin, primary, Roelofsen, Lisanne M., primary, Bonavita, Eduardo, primary, Bell, Charlotte R., primary, Hutton, Colin, primary, Blanco-Gomez, Adrian, primary, Banyard, Antonia, primary, Bromley, Christian P., primary, Flanagan, Eimear, primary, Chiang, Shih-Chieh, primary, Jørgensen, Claus, primary, Schumacher, Ton N., primary, Thommen, Daniela S., primary, and Zelenay, Santiago, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results